Celestra셀레스트라

Celestra is in court-supervised rehabilitation after a rehabilitation termination decision, with heavy losses and negative trailing revenue in the data.

Celestra, a KOSDAQ-listed biotech and pharma company with a market value of about ₩13.6B at ₩5,250 a share, has shrunk sharply since 2021. Its 2025 revenue was ₩2.0B, down 76.4%, with an operating loss of ₩7.8B, and trailing figures to H1 2026 show negative revenue, which the data does not explain. The filings in mid-2026 concern a rehabilitation procedure, a listing-eligibility review and an adverse audit opinion.

What stands out

• Revenue fell from ₩55.4B in 2021 to ₩2.0B in 2025, and trailing revenue to H1 2026 is shown as negative, which is unusual and not explained in the data.
• Net losses were ₩11.8B in 2025 and ₩46.9B in 2024, and equity-based ratios are distorted, with ROE of 1,923.6% and negative liabilities-to-equity.
• Borrowings of about ₩2.5B are well above cash of about ₩0.1B on the trailing figures, and free cash flow was negative at about -₩0.2B.
• Filings in June 2026 cover commencement of rehabilitation proceedings, and in August 2026 a termination decision for that procedure, plus a notice on a 50% or greater capital impairment and an adverse audit opinion.
• Foreign ownership is 2.8% and unchanged over 60 days, and the data contains no news headlines or valuation multiples such as P/E or P/B for the current year.

What to watch

• Whether the Korea Exchange takes any market measures following the rehabilitation termination decision and the listing-eligibility review, as noted in the August 2026 notices.
• The next filings on the capital position, going-concern status and funding, since the data shows capital impairment and an adverse audit opinion.
• The company's head office relocation filed in September 2026 and any further rehabilitation or restructuring filings; the data does not include a results calendar.